[
  {
    "ts": null,
    "headline": "Dow Jones Futures: Nasdaq Breaks Support As Walmart Hits Milestone; AMD, Lumentum Are Earnings Movers Late",
    "summary": "Techs and chips struggled Tuesday, while consumer staples, regional banks, precious metals and industrials are areas of strength. AMD, Lumentum were earnings movers late.",
    "url": "https://finnhub.io/api/news?id=1b049f286e53edb852a0dadce172e05f33d0558acdc48c013ed9c54a4097c75f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770155691,
      "headline": "Dow Jones Futures: Nasdaq Breaks Support As Walmart Hits Milestone; AMD, Lumentum Are Earnings Movers Late",
      "id": 138347061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Techs and chips struggled Tuesday, while consumer staples, regional banks, precious metals and industrials are areas of strength. AMD, Lumentum were earnings movers late.",
      "url": "https://finnhub.io/api/news?id=1b049f286e53edb852a0dadce172e05f33d0558acdc48c013ed9c54a4097c75f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Projects Sales Decline in 2026 Amid Lower US Prices; Shares Slump",
    "summary": "Novo Nordisk (NVO) shares tumbled Tuesday after the company forecast a drop in sales this year due i",
    "url": "https://finnhub.io/api/news?id=a9d18447c5935d9c764e1897aa65088ac8cca0ae61470ee5a955bb6f6dbead1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770150974,
      "headline": "Novo Nordisk Projects Sales Decline in 2026 Amid Lower US Prices; Shares Slump",
      "id": 138347126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) shares tumbled Tuesday after the company forecast a drop in sales this year due i",
      "url": "https://finnhub.io/api/news?id=a9d18447c5935d9c764e1897aa65088ac8cca0ae61470ee5a955bb6f6dbead1a"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drug Bets Get a Reality Check—but Investors Shouldn’t Panic",
    "summary": "Novo Nordisk pre-announced weaker-than-expected guidance, forecasting a 5% to 13% decline in constant-currency sales this year, citing pricing pressure and intensifying competition.  Earlier Tuesday, Pfizer reported underwhelming data for its once-monthly obesity injection, raising fresh doubts about the Metsera acquisition it announced last year, and whether it will be enough to support a blockbuster competitor to the Lilly and Novo injections.  Pfizer shares fell 3.2%, while Novo Nordisk’s American depositary receipts plunged 15%.",
    "url": "https://finnhub.io/api/news?id=4e3a3867cd2a9be5301e0b0e447bd68f31a093fc277bb8c5499383a9b8f64eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770148121,
      "headline": "Obesity Drug Bets Get a Reality Check—but Investors Shouldn’t Panic",
      "id": 138347127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk pre-announced weaker-than-expected guidance, forecasting a 5% to 13% decline in constant-currency sales this year, citing pricing pressure and intensifying competition.  Earlier Tuesday, Pfizer reported underwhelming data for its once-monthly obesity injection, raising fresh doubts about the Metsera acquisition it announced last year, and whether it will be enough to support a blockbuster competitor to the Lilly and Novo injections.  Pfizer shares fell 3.2%, while Novo Nordisk’s American depositary receipts plunged 15%.",
      "url": "https://finnhub.io/api/news?id=4e3a3867cd2a9be5301e0b0e447bd68f31a093fc277bb8c5499383a9b8f64eeb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Crashes After Projecting 2026 Decline; Surprising With Day-Early Report",
    "summary": "Novo Nordisk stock crashed Tuesday after the company said it expects sales and operating profit to decline by 5% to 13% this year.",
    "url": "https://finnhub.io/api/news?id=853f1f58b23fc331837906e9fa1ae172baf58616df968ce721370c8f7b3f57bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770143512,
      "headline": "Novo Crashes After Projecting 2026 Decline; Surprising With Day-Early Report",
      "id": 138345544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock crashed Tuesday after the company said it expects sales and operating profit to decline by 5% to 13% this year.",
      "url": "https://finnhub.io/api/news?id=853f1f58b23fc331837906e9fa1ae172baf58616df968ce721370c8f7b3f57bb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares plunge amid lower 2026 sales outlook",
    "summary": "Investing.com - Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply midday Tuesday after the Wegovy-maker posted fourth-quarter results and issued a sales warning for 2026.",
    "url": "https://finnhub.io/api/news?id=f9ff8d601c037e21ae6f894fb1731274e89c656048512900e53ea4e7894c08fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770140985,
      "headline": "Novo Nordisk shares plunge amid lower 2026 sales outlook",
      "id": 138344068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com - Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply midday Tuesday after the Wegovy-maker posted fourth-quarter results and issued a sales warning for 2026.",
      "url": "https://finnhub.io/api/news?id=f9ff8d601c037e21ae6f894fb1731274e89c656048512900e53ea4e7894c08fc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Falls Ahead of Earnings -- Phase 3 Trials Could Fuel Next Wave of Growth",
    "summary": "LLY Earnings Preview: Medicare Access and New Launches Could Boost Revenue in 2026",
    "url": "https://finnhub.io/api/news?id=b941af9be74926b9b64fab89451f7e8760b200b1a94045b6af6c1dbaf031faba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770139677,
      "headline": "Eli Lilly Stock Falls Ahead of Earnings -- Phase 3 Trials Could Fuel Next Wave of Growth",
      "id": 138344069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY Earnings Preview: Medicare Access and New Launches Could Boost Revenue in 2026",
      "url": "https://finnhub.io/api/news?id=b941af9be74926b9b64fab89451f7e8760b200b1a94045b6af6c1dbaf031faba"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
    "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
    "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138907,
      "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
      "id": 138344070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
      "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight",
    "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
    "url": "https://finnhub.io/api/news?id=953b8a82a1d8001b11b9c5d344aa9550a048c331cdd4bbfae58b2d9288dbc8ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138322,
      "headline": "Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight",
      "id": 138344071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
      "url": "https://finnhub.io/api/news?id=953b8a82a1d8001b11b9c5d344aa9550a048c331cdd4bbfae58b2d9288dbc8ed"
    }
  },
  {
    "ts": null,
    "headline": "Novo warns sales to tumble on tougher competition in US",
    "summary": "The Danish drugmaker’s annual sales last fell in 2017 amid a price war over insulin in the US.  Analysts had anticipated a conservative forecast and a decline in sales, but the magnitude of the potential drop is larger than had been predicted.",
    "url": "https://finnhub.io/api/news?id=4724d7f1f8002dc0ad75a375b5557ae9d498eeba34f80f0c8262fbb709da70ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138156,
      "headline": "Novo warns sales to tumble on tougher competition in US",
      "id": 138344072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish drugmaker’s annual sales last fell in 2017 amid a price war over insulin in the US.  Analysts had anticipated a conservative forecast and a decline in sales, but the magnitude of the potential drop is larger than had been predicted.",
      "url": "https://finnhub.io/api/news?id=4724d7f1f8002dc0ad75a375b5557ae9d498eeba34f80f0c8262fbb709da70ce"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data",
    "summary": "PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.",
    "url": "https://finnhub.io/api/news?id=32b36462779a19e3d05eb7619b1f5e0030dbbdc28fbbd5c806738eb5686b691e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136320,
      "headline": "Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data",
      "id": 138345545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.",
      "url": "https://finnhub.io/api/news?id=32b36462779a19e3d05eb7619b1f5e0030dbbdc28fbbd5c806738eb5686b691e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Drops On Obesity-Drug Study Data",
    "summary": "Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war last year.  The company said the injected drug, PF’3944, helped people lose 12.3% of their body weight versus a placebo after 28 weeks of treatment in a mid-stage clinical trial.  Analysts said the drug’s efficacy was slightly inferior to Eli Lilly’s Zepbound weight-loss drug, and raised concerns about study subjects discontinuing treatment due to side effects.",
    "url": "https://finnhub.io/api/news?id=159db082a43241e4ae26bb3bf8c11188f7149f54d278d4d507ebf47e0a127b4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770132743,
      "headline": "Pfizer Stock Drops On Obesity-Drug Study Data",
      "id": 138344073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war last year.  The company said the injected drug, PF’3944, helped people lose 12.3% of their body weight versus a placebo after 28 weeks of treatment in a mid-stage clinical trial.  Analysts said the drug’s efficacy was slightly inferior to Eli Lilly’s Zepbound weight-loss drug, and raised concerns about study subjects discontinuing treatment due to side effects.",
      "url": "https://finnhub.io/api/news?id=159db082a43241e4ae26bb3bf8c11188f7149f54d278d4d507ebf47e0a127b4c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Weight Loss And Pipeline Bets As Valuation Draws Focus",
    "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to a new Pennsylvania manufacturing facility for next generation injectable weight loss therapies. The company has entered a gene editing collaboration with Seamless Therapeutics targeting certain forms of hearing loss. Lilly also announced a partnership with Repertoire Immune Medicines focused on autoimmune disease therapies. Eli Lilly comes into these moves with its share price at $1,044.13 and a 1 year return of 29.8%. Over 3 years, the stock is...",
    "url": "https://finnhub.io/api/news?id=3da2a210f5c569769675e56a9d2e97d079dd8085bb55d472c2c374bab459b6ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770131345,
      "headline": "Eli Lilly Expands Weight Loss And Pipeline Bets As Valuation Draws Focus",
      "id": 138342543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to a new Pennsylvania manufacturing facility for next generation injectable weight loss therapies. The company has entered a gene editing collaboration with Seamless Therapeutics targeting certain forms of hearing loss. Lilly also announced a partnership with Repertoire Immune Medicines focused on autoimmune disease therapies. Eli Lilly comes into these moves with its share price at $1,044.13 and a 1 year return of 29.8%. Over 3 years, the stock is...",
      "url": "https://finnhub.io/api/news?id=3da2a210f5c569769675e56a9d2e97d079dd8085bb55d472c2c374bab459b6ca"
    }
  },
  {
    "ts": null,
    "headline": "Walmart Hits $1 Trillion Valuation",
    "summary": "Walmart has become the first traditional retailer to command a $1 trillion valuation. In Tuesday morning trading, Walmart stock hit a peak of $126 a share, giving it a market capitalization of $1.004 trillion.",
    "url": "https://finnhub.io/api/news?id=1824254b6c760dbe3034d085e246e2c8395fa9a9a7d53ea08b4fb5a9f943737a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770131047,
      "headline": "Walmart Hits $1 Trillion Valuation",
      "id": 138343983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Walmart has become the first traditional retailer to command a $1 trillion valuation. In Tuesday morning trading, Walmart stock hit a peak of $126 a share, giving it a market capitalization of $1.004 trillion.",
      "url": "https://finnhub.io/api/news?id=1824254b6c760dbe3034d085e246e2c8395fa9a9a7d53ea08b4fb5a9f943737a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight.",
    "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
    "url": "https://finnhub.io/api/news?id=2f121d6b13b77d97de82cb16d13778897921668c5b4b22e8d487318fdc262550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130779,
      "headline": "Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight.",
      "id": 138342544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.",
      "url": "https://finnhub.io/api/news?id=2f121d6b13b77d97de82cb16d13778897921668c5b4b22e8d487318fdc262550"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?",
    "summary": "Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=8edd2714e6bbcaab701c072ff5ba3ad1cfd5aeb945a089bc31b1fa8f07196ea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770129547,
      "headline": "Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?",
      "id": 138344075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=8edd2714e6bbcaab701c072ff5ba3ad1cfd5aeb945a089bc31b1fa8f07196ea4"
    }
  },
  {
    "ts": null,
    "headline": "NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer",
    "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.",
    "url": "https://finnhub.io/api/news?id=f9009a5a2c95ef8fb7412da8100ed45d69b87bff99dcce6d89d9416d61569e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126900,
      "headline": "NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer",
      "id": 138341731,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.",
      "url": "https://finnhub.io/api/news?id=f9009a5a2c95ef8fb7412da8100ed45d69b87bff99dcce6d89d9416d61569e4a"
    }
  },
  {
    "ts": null,
    "headline": "Revvity: Close To A Buy, Not Quite There",
    "summary": "Revvity, Inc. is rated a Hold due to stretched valuation, ongoing weakness in China diagnostics and NIH funding. Read more on RVTY stock here.",
    "url": "https://finnhub.io/api/news?id=8c9aebc69c957cb5511dc5f08bfbb0df7202cbeb6f17869ad668d4577cb1fdb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125752,
      "headline": "Revvity: Close To A Buy, Not Quite There",
      "id": 138344866,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358567692/image_1358567692.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Revvity, Inc. is rated a Hold due to stretched valuation, ongoing weakness in China diagnostics and NIH funding. Read more on RVTY stock here.",
      "url": "https://finnhub.io/api/news?id=8c9aebc69c957cb5511dc5f08bfbb0df7202cbeb6f17869ad668d4577cb1fdb2"
    }
  },
  {
    "ts": null,
    "headline": "Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly",
    "summary": "ZHUZHOU, China, February 03, 2026--Zonsen PepLib Biotech Inc. (\"PepLib\") today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company (\"Lilly\"). Under the agreement, both parties will jointly advance the development of novel peptide-based drug candidates leveraging PepLib’s robust and diverse proprietary peptide libraries and discovery technology platforms.",
    "url": "https://finnhub.io/api/news?id=15f069d0bd941f9959590009e1b6b8358c5793933d5a7c6beb4521946687cc65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123600,
      "headline": "Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly",
      "id": 138341601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ZHUZHOU, China, February 03, 2026--Zonsen PepLib Biotech Inc. (\"PepLib\") today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company (\"Lilly\"). Under the agreement, both parties will jointly advance the development of novel peptide-based drug candidates leveraging PepLib’s robust and diverse proprietary peptide libraries and discovery technology platforms.",
      "url": "https://finnhub.io/api/news?id=15f069d0bd941f9959590009e1b6b8358c5793933d5a7c6beb4521946687cc65"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Merck (MRK) delivered earnings and revenue surprises of +0.62% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=b527a90efab2910fc1bd4db7f9db4b65c6414decd1b78bab57dc3e9474082d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770122402,
      "headline": "Merck (MRK) Q4 Earnings and Revenues Beat Estimates",
      "id": 138342546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered earnings and revenue surprises of +0.62% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=b527a90efab2910fc1bd4db7f9db4b65c6414decd1b78bab57dc3e9474082d7c"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Eli Lilly “Could Announce Some New Data, and That Could Get the Stock Rolling”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted what “drives the stock,” as he remarked: Wednesday morning, Eli Lilly reports. Its earnings haven’t been the propellant here. What drives the stock are new reports on GLP-1 clinical trials. But Lilly could announce some new data, […]",
    "url": "https://finnhub.io/api/news?id=e0f345b0f5046d07199889d3ed677b7360d80025ebcce20c45c4777244e1776b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121448,
      "headline": "Jim Cramer Says Eli Lilly “Could Announce Some New Data, and That Could Get the Stock Rolling”",
      "id": 138341530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted what “drives the stock,” as he remarked: Wednesday morning, Eli Lilly reports. Its earnings haven’t been the propellant here. What drives the stock are new reports on GLP-1 clinical trials. But Lilly could announce some new data, […]",
      "url": "https://finnhub.io/api/news?id=e0f345b0f5046d07199889d3ed677b7360d80025ebcce20c45c4777244e1776b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer dips on new data for obesity drug acquired in $10B deal",
    "summary": "A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.",
    "url": "https://finnhub.io/api/news?id=caa2caf3fb3064ba4b8125d4ea167f7129296b233014f6d201e11bb1efdf4a06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120060,
      "headline": "Pfizer dips on new data for obesity drug acquired in $10B deal",
      "id": 138344076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.",
      "url": "https://finnhub.io/api/news?id=caa2caf3fb3064ba4b8125d4ea167f7129296b233014f6d201e11bb1efdf4a06"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares tumble after company forecasts sales declines this year",
    "summary": "The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.",
    "url": "https://finnhub.io/api/news?id=180e6a0c81fc2ae8eace7b10e4222f65a0a043a47754f83fa67814509f625e6e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119822,
      "headline": "Novo Nordisk shares tumble after company forecasts sales declines this year",
      "id": 138343603,
      "image": "https://image.cnbcfm.com/api/v1/image/108247614-1767376953845-gettyimages-2253792477-US_STOCKS.jpeg?v=1767377112&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market. ",
      "url": "https://finnhub.io/api/news?id=180e6a0c81fc2ae8eace7b10e4222f65a0a043a47754f83fa67814509f625e6e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) to Invest Over $3.5 Billion in New Manufacturing Facility in Pennsylvania",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device […]",
    "url": "https://finnhub.io/api/news?id=32e902b230dc99420be40e68601c60c80d54c022324519b3cba077defec27987",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770111252,
      "headline": "Eli Lilly and Company (LLY) to Invest Over $3.5 Billion in New Manufacturing Facility in Pennsylvania",
      "id": 138340020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device […]",
      "url": "https://finnhub.io/api/news?id=32e902b230dc99420be40e68601c60c80d54c022324519b3cba077defec27987"
    }
  },
  {
    "ts": null,
    "headline": "Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity",
    "summary": "Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity",
    "url": "https://finnhub.io/api/news?id=163aa763f1452ce000e63fc79185f7d0655bc53994eb7f8fb8c486efa66906af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770108753,
      "headline": "Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity",
      "id": 138341617,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=163aa763f1452ce000e63fc79185f7d0655bc53994eb7f8fb8c486efa66906af"
    }
  },
  {
    "ts": null,
    "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
    "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770105706,
      "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138340001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
      "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial",
    "summary": "The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.",
    "url": "https://finnhub.io/api/news?id=47e093d0159af6de77cf8251abecb9a741e175f28d7c0be878bd717388a257ec",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770103115,
      "headline": "Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial",
      "id": 138343604,
      "image": "https://image.cnbcfm.com/api/v1/image/108218653-1761752333854-gettyimages-2243676983-299665final.jpeg?v=1770120637&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy. ",
      "url": "https://finnhub.io/api/news?id=47e093d0159af6de77cf8251abecb9a741e175f28d7c0be878bd717388a257ec"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s New Weight Loss Plant And What It Might Mean For LLY’s Valuation",
    "summary": "Eli Lilly’s new Pennsylvania build and why it matters for the stock Eli Lilly (LLY) has drawn fresh attention after outlining plans to invest more than US$3.5b in a Pennsylvania facility dedicated to injectable weight loss medicines, including the experimental drug retatrutide. The project sits alongside upbeat analyst commentary on Lilly’s obesity and diabetes portfolio and a closely watched earnings report this week, which together put the company’s weight management franchise and capital...",
    "url": "https://finnhub.io/api/news?id=9e8c2ea8431e9180d81c33fb7d3423552bd8e294894ee573f3938a9fdf3ed786",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770088499,
      "headline": "Eli Lilly’s New Weight Loss Plant And What It Might Mean For LLY’s Valuation",
      "id": 138338515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s new Pennsylvania build and why it matters for the stock Eli Lilly (LLY) has drawn fresh attention after outlining plans to invest more than US$3.5b in a Pennsylvania facility dedicated to injectable weight loss medicines, including the experimental drug retatrutide. The project sits alongside upbeat analyst commentary on Lilly’s obesity and diabetes portfolio and a closely watched earnings report this week, which together put the company’s weight management franchise and capital...",
      "url": "https://finnhub.io/api/news?id=9e8c2ea8431e9180d81c33fb7d3423552bd8e294894ee573f3938a9fdf3ed786"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Q4: Everything You Need To Know Ahead Of Earnings",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Wednesday before market hours. Here’s what to expect.",
    "url": "https://finnhub.io/api/news?id=a41176ae5759c8433e9204099861676689774f1488f9a4bd6bab78ffa0a546c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770088403,
      "headline": "Eli Lilly (LLY) Reports Q4: Everything You Need To Know Ahead Of Earnings",
      "id": 138338516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Wednesday before market hours. Here’s what to expect.",
      "url": "https://finnhub.io/api/news?id=a41176ae5759c8433e9204099861676689774f1488f9a4bd6bab78ffa0a546c0"
    }
  },
  {
    "ts": null,
    "headline": "Google, Amazon, Nvidia Lead Earnings Barrage. Here's How To Get Ready.",
    "summary": "Welcome to a revamped How To Invest newsletter as upcoming earnings from Google, Amazon and more bring these rules into focus.",
    "url": "https://finnhub.io/api/news?id=f1c804d4e4b3cda55226ef5b151b523ef615a839311fc74e9b22ad4b874b42ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770083455,
      "headline": "Google, Amazon, Nvidia Lead Earnings Barrage. Here's How To Get Ready.",
      "id": 138337917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Welcome to a revamped How To Invest newsletter as upcoming earnings from Google, Amazon and more bring these rules into focus.",
      "url": "https://finnhub.io/api/news?id=f1c804d4e4b3cda55226ef5b151b523ef615a839311fc74e9b22ad4b874b42ca"
    }
  },
  {
    "ts": null,
    "headline": "AbCellera Biologics Inc. (ABCL): A Bull Case Theory",
    "summary": "We came across a bullish thesis on AbCellera Biologics Inc. on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc.’s share was trading at $3.6200 as of January 21st. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet […]",
    "url": "https://finnhub.io/api/news?id=f3863cc0f251d972c6ff89e30e42c03a7ebd944948bb916f5c8baca114378b81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770079791,
      "headline": "AbCellera Biologics Inc. (ABCL): A Bull Case Theory",
      "id": 138337963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on AbCellera Biologics Inc. on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc.’s share was trading at $3.6200 as of January 21st. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet […]",
      "url": "https://finnhub.io/api/news?id=f3863cc0f251d972c6ff89e30e42c03a7ebd944948bb916f5c8baca114378b81"
    }
  }
]